



From Antibody Fragments to Therapeutic Manufacturing: Challenges and the Future of Antibody Synthesis

Guest Editors:

Dr. Monica Berrondo

Macromoltek, Inc., 2500 W
William Cannon Dr, Suite 204,
Austin, TX 78745, USA

monica@macromoltek.com

Prof. Dr. Robert H. Carnahan

1. The Vanderbilt Vaccine Center,
Vanderbilt University Medical
Center, Nashville, TN 27232, USA
2. Department of Pediatrics,
Vanderbilt University Medical
Center, Nashville, TN 27232, USA

robert.carnahan@vanderbilt.edu

Deadline for manuscript
submissions:

closed (20 July 2021)

Message from the Guest Editors

With the explosive growth in the antibody therapeutics market comes the increasing need to create higher-quality antibody proteins using time- and cost-effective strategies. Protein synthesis is a rapidly evolving field with a broad diversity of techniques. Antibody protein synthesis, particularly, requires constant innovation to create better research tools, diagnostics, and therapeutics. Expression systems, scale, and techniques vary widely from recombinant expression in prokaryotes to mammalian cell culture expression, cell-free expression, monoclonal vs. polyclonal, fragments, isotypes, multi-specifics, library generation, and many others. The Special Issue “From Antibody Fragments to Therapeutic Manufacturing: Challenges and the Future of Antibody Synthesis” aims to kindle discussion of current and innovative methods of antibody production. We invite experts to share manuscripts describing their choice of antibody synthesis method, advantages, disadvantages, and innovations from preclinical proof-of-concept to large-scale manufacturing of antibody or antibody-like proteins intended for research, diagnostics, or therapeutic applications.





Editor-in-Chief

Prof. Dr. Arne Skerra

Chair of Biological Chemistry,
Technical University of Munich,
Emil-Erlenmeyer-Forum 5, 85354
Freising (Weihenstephan),
Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.8 days after submission; acceptance to publication is undertaken in 3.8 days (median values for papers published in this journal in the second half of 2022).

Contact Us

Antibodies
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibodies
antibodies@mdpi.com
 @Antibodies_MDPI